Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the IAS Q3 ...

Editorial Note: Blueprint may earn a commission from affiliate partner links featured here on our site. This commission does not influence our editors' opinions or evaluations. Please view our ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

Sanofi gets rated buy today ... as it has been driving revenue from multiple products rather than a single magic drug.

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

It has its own manufacturing facility at Goa. It sells products through independent distributors primarily in India.Sanofi India's products viz. Lantus Combiflam Amaryl and Allegra feature in the top ...

The third new business unit – emerging markets – bundles Sanofi's generic medicines and older products still in patent with the company's consumer healthcare products, emphasising that in ...